Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial - Home, PD; Pocock, SJ; Beck-Nielsen, H (Lancet, 2009)
et al.